Elevance Health, Inc. $ELV Shares Sold by TD Asset Management Inc

TD Asset Management Inc trimmed its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 15.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 174,578 shares of the company’s stock after selling 30,934 shares during the quarter. TD Asset Management Inc owned about 0.08% of Elevance Health worth $56,410,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Ashton Thomas Private Wealth LLC acquired a new position in Elevance Health in the 2nd quarter valued at $1,162,000. Transcend Capital Advisors LLC raised its stake in shares of Elevance Health by 6.6% during the 2nd quarter. Transcend Capital Advisors LLC now owns 876 shares of the company’s stock worth $341,000 after buying an additional 54 shares in the last quarter. Howard Capital Management Inc. lifted its holdings in shares of Elevance Health by 25.9% in the 2nd quarter. Howard Capital Management Inc. now owns 1,659 shares of the company’s stock valued at $645,000 after buying an additional 341 shares during the period. Arkadios Wealth Advisors boosted its stake in shares of Elevance Health by 56.4% in the second quarter. Arkadios Wealth Advisors now owns 3,021 shares of the company’s stock valued at $1,175,000 after buying an additional 1,089 shares in the last quarter. Finally, Hantz Financial Services Inc. grew its holdings in Elevance Health by 116.4% during the second quarter. Hantz Financial Services Inc. now owns 277 shares of the company’s stock worth $108,000 after acquiring an additional 149 shares during the period. Institutional investors and hedge funds own 89.24% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on ELV shares. UBS Group set a $400.00 target price on Elevance Health in a report on Thursday, January 29th. Wolfe Research set a $425.00 price objective on shares of Elevance Health and gave the company an “outperform” rating in a research note on Thursday, January 8th. TD Cowen reissued a “buy” rating on shares of Elevance Health in a report on Wednesday, November 26th. Guggenheim dropped their target price on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a report on Thursday, January 29th. Finally, Morgan Stanley reduced their price target on shares of Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 17th. Twelve investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $390.55.

Elevance Health Stock Performance

Elevance Health stock opened at $322.94 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $458.75. The firm’s fifty day moving average price is $350.62 and its 200 day moving average price is $335.19. The company has a market capitalization of $71.28 billion, a price-to-earnings ratio of 12.86, a price-to-earnings-growth ratio of 1.83 and a beta of 0.50.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The firm had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. During the same period in the prior year, the firm posted $3.84 EPS. The firm’s revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, research analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be given a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s payout ratio is 27.23%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.